Fig. 5.

High frequency of CD56⁻CD16⁺ NK cells at diagnosis is associated with adverse clinical outcome. (A) Frequency of CD56⁻CD16⁺ NK cells in AML patients at diagnosis according to clinical outcome after 24 mo of follow up. (B) Patients were stratified according to the frequency of CD56⁻CD16⁺ NK cells (group 1: CD56⁻CD16⁺ NK cells ≤10%; group 2: CD56⁻CD16⁺ NK cells >10%). The impact of the accumulation of CD56⁻CD16⁺ NK cells on OS, EFS and relapse-free was assessed using a log-rank test. CI95, 95% confidence interval; CR, complete remission; HR, hazard ratio; and UPN, unique patient number.